...
首页> 外文期刊>Biomolecules >Discovery of Orexant and Anorexant Agents with Indazole Scaffold Endowed with Peripheral Antiedema Activity
【24h】

Discovery of Orexant and Anorexant Agents with Indazole Scaffold Endowed with Peripheral Antiedema Activity

机译:用吲唑支架的厌氧和厌食剂的发现赋予外周抗腹部活动

获取原文
           

摘要

The endocannabinoid system represents an integrated neuronal network involved in the control of several organisms’ functions, such as feeding behavior. A series of hybrids of 5-(4-chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl- N -(piperidin-1-yl)-1 H -pyrazole-3-carboxamide (mimonabant), a well-known inverse agonist of the type-1 cannabinoid receptor (CB1), once used as an antiobesity drug, and the N -(2 S )-substitutes of 1-[(4-fluorophenyl)methyl]indazole-3-carboxamide with 1-amino-3-methyl-1-oxobutane (AB-Fubinaca), 1-amino-3,3-dimethyl-1-oxobutane (ADB-Fubinaca), and 3-methylbutanoate (AMB-Fubinaca), endowed with potent agonistic activity towards cannabinoid receptors CB1 and CB2 were in solution as C -terminal amides, acids, methyl esters and N -methyl amides. These compounds have been studied by binding assays to cannabinoid receptors and by functional receptor assays, using rat brain membranes in vitro. The most active among them as an agonist, (S)-1-(2,4-dichlorobenzyl)- N -(3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-1H-indazole-3-carboxamide (LONI11), and an antagonist, (S)-2-(1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoic acid (LONI4), were tested in vivo in mic, to evaluate their ability to stimulate or suppress feeding behavior after intraperitoneal (i.p.) administration. For a LONI11 formalin test and a tail flick test after an administration by the subcutaneous (s.c.) and intracerebroventricular (i.c.v.) routes, respectively, were also carried out in vivo in mice to investigate the antinociceptive property at the central and peripheral levesl. We observed a significant orexant effect for LONI11 and an intense anorexant effect for (S)-methyl 2-(1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (LONI2) and LONI4. In zymosan-induced edema and hyperalgesia, LONI11 reduced the percent of paw volume increase and paw latency after s.c. administration, also suggesting a possible peripheral anti-inflammatory activity.
机译:内突造称系统代表了涉及若干生物体功能的集成神经元网络,例如喂养行为。一系列5-(4-氯苯基)-1-(2,4-二氯 - 苯基)-4-甲基-N-(哌啶-1-基)-1H-吡唑-3-甲酰胺(Mimonabant)的杂种,一份众所周知的1型大麻素受体(CB1)的逆激动剂,一次用作抗菌药物,以及1 - [(4-氟苯基)甲基]吲唑-3-的N - (2 S) - 吲唑-3-用1-氨基-3-甲基-1-氧脱丁烷(AB-FUBINACA),1-氨基-3,3-二甲基-1-氧脱丁烷(ADB-FUBINACA)和3-甲基丁醇(AMB-FUBINACA)的羧酰胺,赋予朝向大麻素受体CB1和CB2的有效的激动活性在溶液中作为C-酸胺酰胺,酸,甲酯和N-甲基酰胺。已经通过在体外使用大鼠脑膜结合到大麻素受体和功能受体测定来研究这些化合物。其中最活跃的是激动剂,(S)-1-(2,4-二氯苄基) - N - (3,3-二甲基-1-(甲基氨基)-1-氧脱丁烷-2-基)-1H-吲唑在体内测试-3-甲酰胺(LONI11)和拮抗剂,(S)-2-(1-(2,4-二氯苄基)-1H-吲唑-3-羧酰胺)-3-甲基丁酸(LONI4)。在麦克风中,评估它们在腹膜内(IP)给药后刺激或抑制喂养行为的能力。对于甲状腺蛋白试验和尾部轻弹试验,在通过皮下(S.C.)和脑室内(I.C.V.)途径分别在小鼠体内进行,以研究中央和外周左侧的抗血质病性能。我们观察到对LONI11的显着反馈效果和(S) - 甲基2-(1-(2,4-二氯苄基)-1H-吲唑-3-羧酰胺)-3,3-二甲基丁醇(LONI2)和浓度的厌氧作用loni4。在酵母诱导的水肿和痛觉中,LONI11降低了爪子体积增加和爪子延迟的百分比。施用,也表明可能的外周抗炎活动。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号